iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 us Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time Eli Lilly and Company brand

GLP-1 medications like semaglutide and tirzepatide work differently: they slow gastric emptying so you feel full longer and act on appetite regulation in the brain, which many patients describe as quieting constant thoughts about food

If theyre still there but dormant, certain peptides can wake them up

In conclusion, our study conducted within real-world clinical settings revealed a noteworthy association between the use of GLP-1 RAs, including Liraglutide and Semaglutide, and a heightened risk of psychiatric outcomes, encompassing depression, anxiety, and suicidal behaviour

This risk may increase when protein intake is low or when people do not do resistance exercise

Wegovy Big picture view: Zepbound and Wegovy are both GLP-1 drugs approved for weight loss, but Zepbound targets two hormones, GIP and GLP-1, while Wegovy only targets GLP-1

The acquisition was done in cash, reflecting Novos strong balance sheet, and avoiding equity dilution